Glenmark Pharma: A Healthy Dose Of Growth

Glenmark, which has graduated to a global organisation in a very short span with its expanded manufacturing footprint, international operations and global employee base, reported a 276.08 per cent rise in revenue since 2012

Glenmark Stock Up After US Approval To Its Savella Generic

Shares of drug maker Glenmark Pharmaceuticals rose 0.52 per cent to Rs 868. 45 a unit on BSE on Friday, a day that saw the benchmark Sensex down by at least 50 points

Glenmark, Evestra To Jointly Develop And Sell NuvaRing Copy In US

Drug maker Glenmark and Evestra Inc, a San Antonio-based biopharmaceutical research and development company with focus in women’s healthcare, have signed a licensing and commercialization agreement for development and marketing of a generic version of Merck & Co.’s NuvaRing, for the US market

Glenmark Gets US Approval For Banzel Generic With 6-Month Exclusivity

The company said it is eligible for 180 days of shared generic drug marketing exclusivity for rufinamide tablets

Pharmaceutical Sector Grows 12 Per Cent In February: Report

Domestic companies grew at a modest pace of 14 per cent as against 19.4 per cent in the same period last year, and an average of 13.3 per cent since April 2015

Glenmark Q3 Net Up 48 Per Cent On Robust US, India Sales

While the company's US business grew about 20 per cent to Rs 608.86 crore, the India business posted a growth of 12.69 per cent to Rs 488 crore during the quarter

Glenmark To Partner Celon For Seretide Generic

Delhi Court Rules In Favour Of US Firm In Anti-Diabetes Drug Case

Glenmark’s New Biological Drug Candidate For Breast Cancer Enters Clinical Trial

Glenmark Shares Rise After US Approval Of Seasonale Copy

Supreme Court Bars Glenmark From Selling Merck Drug Copies

Supreme Court Bars Glenmark From Selling Merck Drug Copies

Always Stay Grounded

UCB Files Cases Against Ranbaxy, Sun Pharma, Others On Patent Issue

Merck Wins Injunction Against India's Aprica Pharma